Skip to main content

Table 4 Efficacy measures between two treatments from GI Discomfort Questionnaire

From: Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study

Parameter

Visit

Placebo

Active

P value

Bloating

Baseline

5.31 ± 0.82

5.88 ± 0.93

0.1372

Final Visit

5.93 ± 0.21

3.42 ± 0.31

0.0037*

Vomiting

Baseline

4.88 ± 0.93

4.02 ± 0.55

0.1126

Final Visit

4.42 ± 0.36

2.13 ± 0.19

0.0013*

Diarrhea

Baseline

5.79 ± 0.95

5.70 ± 0.76

0.1684

Final Visit

5.93 ± 0.54

3.25 ± 0.42

0.0026*

Stool frequency

Baseline

5.41 ± 0.68

5.67 ± 0.58

0.1485

Final Visit

5.75 ± 0.11

3.11 ± 0.27

0.0031*

Abdominal pain

Baseline

5.64 ± 0.77

5.71 ± 0.11

0.1539

Final Visit

5.93 ± 0.21

1.82 ± 0.49

0.0001*

  1. Values expressed as mean ± S.E
  2. *Statistically significant